Korro Bio, Inc. Debt Securities, Available-for-sale, Unrealized Loss
Korro Bio, Inc. (KRRO) reported Debt Securities, Available-for-sale, Unrealized Loss of $274.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2026-08-06
- Korro Bio, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2026-06-30 was $171.00K.
- Korro Bio, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2026-03-31 was $103.00K, a 139.53% increase year-over-year.
- Korro Bio, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-12-31 was -$7.00K, a 107.14% decline year-over-year.
- Korro Bio, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-09-30 was -$26.00K.
- Korro Bio, Inc. debt securities, available-for-sale, unrealized loss for fiscal 2024 was $98.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2026-06-30 | $171.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $274.00K 10-Q · filed 2026-08-06 | $267.00K derived: sum of 3 quarters · filed 2026-08-06 | $241.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $103.00K 10-Q · filed 2026-05-07 | $96.00K derived: sum of 2 quarters · filed 2026-08-06 | $70.00K derived: sum of 3 quarters · filed 2026-08-06 | $60.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$7.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-06 | -$33.00K derived: sum of 2 quarters · filed 2026-08-06 | -$43.00K derived: sum of 3 quarters · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$26.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$36.00K derived: sum of 2 quarters · filed 2025-11-12 | $7.00K 10-Q · filed 2025-11-12 | $105.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-06-30 | -$10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $33.00K 10-Q · filed 2025-08-12 | $131.00K derived: sum of 3 quarters · filed 2026-03-12 | $119.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-03-31 | $43.00K 10-Q · filed 2025-05-07 | $141.00K derived: sum of 2 quarters · filed 2026-03-12 | $129.00K derived: sum of 3 quarters · filed 2026-03-12 | |
| 2024-12-31 | $98.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $86.00K derived: sum of 2 quarters · filed 2026-03-12 | $98.00K 10-K · filed 2026-03-12 | |
| 2024-09-30 | -$12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | $12.00K 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |